Show simple item record

dc.contributor.authorLYNCH, MARINA ANNETTAen
dc.date.accessioned2012-06-27T14:41:58Z
dc.date.available2012-06-27T14:41:58Z
dc.date.issued2012en
dc.date.submitted2012en
dc.identifier.citationBunmi Ojo, Payam Rezaie, Paul L. Gabbott, Heather Davies, Frances Colyer, Thelma R. Cowley, Marina Lynch, Michael G. Stewart, Age-related changes in the hippocampus (loss of synaptophysin and glial-synaptic interaction) are modified by systemic treatment with an NCAM-derived peptide, FGL, Brain, Behavior, and Immunity, 26, 5, 2012, 778-88en
dc.identifier.otherYen
dc.identifier.urihttp://hdl.handle.net/2262/64050
dc.descriptionPUBLISHEDen
dc.description.abstractAltered synaptic morphology, progressive loss of synapses and glial (astrocyte and microglial) cell activation are considered as characteristic hallmarks of ageing. Recent evidence suggests that there is a concomitant age-related decrease in expression of the presynaptic protein, synaptophysin, and the neuronal glycoprotein CD200, which, by interacting with its receptor, plays a role in maintaining microglia in a quiescent state. These age-related changes may be indicative of reduced neuroglial support of synapses. FG Loop (FGL) peptide synthesised from the second fibronectin type III module of neural cell adhesion molecule (NCAM), has previously been shown to attenuate age-related glial cell activation, and to `restore? cognitive function in aged rats. The mechanisms by which FGL exerts these neuroprotective effects remain unclear, but could involve regulation of CD200, modifying glial-synaptic interactions (affecting neuroglial `support? at synapses), or impacting directly on synaptic function. Light and electron microscopic (EM) analyses were undertaken to investigate whether systemic treatment with FGL (i) alters CD200, synaptophysin (presynaptic) and PSD95 (postsynaptic) immunohistochemical expression levels, (ii) affects synaptic number, or (iii) exerts any effects on glial-synaptic interactions within young (4 month-old) and aged (22 month-old) rat hippocampus. Treatment with FGL attenuated the age-related loss of synaptophysin immunoreactivity (-ir) within CA3 and hilus (with no major effect on PSD-95-ir), and of CD200-ir specifically in the CA3 region. Ultrastructural morphometric analyses showed that FGL treatment (i) prevented age-related loss in astrocyte-synaptic contacts, (ii) reduced microglia-synaptic contacts in the CA3 stratum radiatum, but (iii) had no effect on the mean number of synapses in this region. These data suggest that FGL mediates its neuroprotective effects by regulating glial-synaptic interaction.en
dc.description.sponsorshipSupported by the European Union FPVI ?Promemoria? programme grant (Contract No. 512012) and FP7 `MemStick? (Ref: 201600)en
dc.format.extent778-88en
dc.language.isoenen
dc.relation.ispartofseriesBrain, Behavior, and Immunityen
dc.relation.ispartofseries26en
dc.relation.ispartofseries5en
dc.rightsYen
dc.subjectNeuroscienceen
dc.subjectAgeingen
dc.subjectHippocampusen
dc.subjectCA3en
dc.subjectastrocytesen
dc.subjectmicrogliaen
dc.subjectCD200en
dc.subjectsynaptophysinen
dc.subjectPSD-95en
dc.subjectmorphometric analysisen
dc.subjectimmunoelectron microscopyen
dc.titleAge-related changes in the hippocampus (loss of synaptophysin and glial-synaptic interaction) are modified by systemic treatment with an NCAM-derived peptide, FGLen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/lynchmaen
dc.identifier.rssinternalid75238en


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record